Ibrance Joins Rival CDK4/6 Inhibitors In English Cancer Drugs Fund
Pfizer’s Ibrance has won conditional reimbursement in England while more data is gathered to reduce some uncertainty.
You may also be interested in...
The Cancer Drugs Fund has improved access to oncology drugs, but if it is to remain fit for purpose it will need to evolve.
Health technology assessment body NICE says that Verzenios when used with fulvestrant can be used to treat advanced breast cancer via the Cancer Drugs Fund, giving Eli Lilly the edge in this space for now over rival CDK4/6 manufacturers, Pfizer and Novartis.